Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 4,710,000 shares, an increase of 1,022.5% from the December 15th total of 419,600 shares. Based on an average daily volume of 6,840,000 shares, the days-to-cover ratio is presently 0.7 days.

Vincerx Pharma Stock Down 1.8 %

VINC stock opened at $0.17 on Wednesday. Vincerx Pharma has a twelve month low of $0.16 and a twelve month high of $9.37. The stock has a market capitalization of $5.64 million, a price-to-earnings ratio of -0.16 and a beta of 1.48. The firm’s fifty day simple moving average is $0.24 and its two-hundred day simple moving average is $0.49.

Analyst Ratings Changes

Separately, Leerink Partners cut their target price on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Vincerx Pharma stock. Armistice Capital LLC acquired a new stake in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,988,000 shares of the company’s stock, valued at approximately $1,610,000. Armistice Capital LLC owned about 6.70% of Vincerx Pharma as of its most recent SEC filing. 44.02% of the stock is owned by hedge funds and other institutional investors.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.